We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-21.22%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.48B
AUM Growth
-$2.59B
Cap. Flow
-$1.26B
Cap. Flow %
-13.32%
Top 10 Hldgs %
78.76%
Holding
139
New
5
Increased
29
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$300M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$200M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$81.4M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$68.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$313M
2
GILD icon
Gilead Sciences
GILD
+$25.3M
3
MDVN
MEDIVATION, INC.
MDVN
+$12M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$4.31M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 77.25%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTN
101
Palatin Technologies
PTN
$14.1M
$1.11M 0.01%
1,640
– –
GWPH
102
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.08M 0.01%
+15,000
New +$823K
TENX icon
103
Tenax Therapeutics
TENX
$399M
$861K 0.01%
13
– –
ADAP
104
DELISTED
Adaptimmune Therapeutics
ADAP
$813K 0.01%
100,000
– –
FPRX
105
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$782K 0.01%
19,247
– –
XLRN
106
DELISTED
Acceleron Pharma
XLRN
$759K 0.01%
28,765
– –
ABUS icon
107
Arbutus Biopharma
ABUS
$845M
$746K 0.01%
180,582
– –
ALNY icon
108
Alnylam Pharmaceuticals
ALNY
$38.1B
$712K 0.01%
11,340
– –
BDSI
109
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$678K 0.01%
210,021
– –
ALDX icon
110
Aldeyra Therapeutics
ALDX
$95.3M
$595K 0.01%
142,000
– –
CMRX
111
DELISTED
Chimerix, Inc.
CMRX
$589K 0.01%
115,216
– –
AIXC
112
AIxCrypto Holdings Inc
AIXC
$13.9M
$452K ﹤0.01%
3
– –
WINT
113
DELISTED
Windtree Therapeutics Inc
WINT
$426K ﹤0.01%
254,973
-2
-0% -$4
FMI
114
DELISTED
Foundation Medicine, Inc.
FMI
$380K ﹤0.01%
20,892
– –
LJPC
115
DELISTED
La Jolla Pharmaceutical Company
LJPC
$287K ﹤0.01%
13,746
– –
AKAO
116
DELISTED
Achaogen Inc
AKAO
$276K ﹤0.01%
100,000
– –
CCXI
117
DELISTED
ChemoCentryx, Inc.
CCXI
$122K ﹤0.01%
49,064
– –
APTO
118
DELISTED
Aptose Biosciences, Inc.
APTO
$100K ﹤0.01%
74
– –
BGMSP
119
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$76K ﹤0.01%
13,253
– –
BTX.WS
120
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$12K ﹤0.01%
20,084
– –
GILD icon
121
Gilead Sciences
GILD
$166B
– –
-249,995
Closed -$25.3M
MRNS
122
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-50,000
Closed -$1.53M
NBSE
123
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-926
Closed -$2.27M
FLXN
124
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-146,642
Closed -$2.83M
DYAX
125
DELISTED
DYAX CORPORATION
DYAX
– –
-8,310,017
Closed -$313M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Baker Bros. Advisors held 139 positions worth $9.48B, down 21% from $12.1B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Baker Bros. Advisors withdrew a net $1.26B in Q1 2016, closing 5 positions and reducing 8 holdings. Its most notable exit was DYAX CORPORATION, an estimated $313M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 73% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in BeOne Medicines Ltd worth $56.1M.

  • Baker Bros. Advisors's largest Q1 2016 buy was BeOne Medicines Ltd: 1,912,680 shares worth $56.1M.
  • Baker Bros. Advisors added most to Incyte in Q1 2016, an estimated $300M increase.
  • Baker Bros. Advisors's biggest Q1 2016 reduction was MEDIVATION, INC., cutting an estimated $12M.
  • Baker Bros. Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $313M.
  • Baker Bros. Advisors's ten largest holdings make up 79% of its $9.48B portfolio in Q1 2016.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q1 2016.
  • Baker Bros. Advisors's portfolio value fell 21% quarter-over-quarter to $9.48B.

Based on Baker Bros. Advisors's 13F filing for Q1 2016, filed 16 May 2016.